The collaboration brings together two complementary technologies: C-RAD’s Catalyst⁺ HD platform, which provides patient setup and real-time motion monitoring, and SeeTreat’s ART.1, which delivers automated adaptive plan decision support for every patient at every treatment. Together, the two platforms span the complete radiotherapy session — from the moment the patient enters the room to the clinical decision about whether their treatment plan remains optimal.

The partnership responds to a growing clinical demand for radiotherapy workflows that are not only more accurate and precise, but also faster, safer, and more personalised. Catalyst⁺ HD and ART.1 address different but deeply connected stages of every treatment session. By exploring how these two platforms can work in concert, C-RAD and SeeTreat aim to support clinical teams in making faster, better-informed decisions to improve patient care. Both companies share a commitment to bringing advances to radiotherapy departments of all sizes and any treatment machines — from major cancer centres to community clinics where resources may be limited, but the need for precision and efficiency is just as critical.

"This partnership opens an exciting new frontier in personalised cancer care. Catalyst⁺ HD gives clinical teams unmatched real-time visibility of the patient, and we believe combining this with SeeTreat’s intelligent adaptive decision support has the power to transform reactive oversight into confident, real-time clinical decision-making, every single fraction." shares Chief Product & Technology Officer, Dr Eeva-Liisa Karjalainen.

“C-RAD has set the global benchmark for Surface Guided Radiation Therapy, and their focus on user-friendly, patient-centric technology aligns strongly with our own values at SeeTreat. This partnership is a significant step toward our shared vision of making personalised radiotherapy accessible for every patient in every clinic.” said CEO and Founder of SeeTreat, Dr Trang Nguyen.

The companies will collaborate to explore clinical needs and product development opportunities that benefit clinicians and patients alike. Further details will be announced later in 2026.

Clinical teams interested in learning more are invited to meet C-RAD and SeeTreat at ESTRO 2026 in Stockholm.

For further information:
Tomas Blomquist, CEO, +46 (0)70 523 0163, investors@c-rad.com
Linda Frölén, CFO, +46 (0)70 303 3253, investors@c-rad.com

About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

About SeeTreat
SeeTreat is doctor backed, physics led, software medical device company founded in 2023, led by Dr Trang Nguyen, Ms Antonia Dalton and Professor Paul Keall. Our vision is to reduce the burden of cancer through broadly accessible software technology that improve quality and accuracy of treatment. SeeTreat is a global company with a current install base in the UK, Europe, USA and Australia. SeeTreat ART.1 product for offline adaptive assessment is the world-first automated software for adaptive radiotherapy. Our headquarters are based in Sydney, Australia.

For more information, visit https://www.seetreatmedical.com/.